CSS
CADL icon

Cubist Systematic Strategies’s Candel Therapeutics CADL Stock Holding History

Cubist Systematic Strategies’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,475
Closed -$144K – 3042
2025
Q2 		$144K Buy
+28,475
New +$147K ﹤0.01% 2659
2024
Q3 		– Sell
-26,121
Closed -$162K – 3017
2024
Q2 		$162K Buy
+26,121
New +$196K ﹤0.01% 2550

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cubist Systematic Strategies's CADL Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Candel Therapeutics (CADL) in Q3 2025, closing a stake of 28,475 shares — an estimated $144K sold.

Cubist Systematic Strategies first reported a position in CADL in Q2 2024 and held it in 2 quarters. The position peaked at $162K in Q2 2024. 81 funds tracked by Wall St. Rank hold CADL as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Candel Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 28,475 Candel Therapeutics shares in Q3 2025, an estimated $144K.
  • Cubist Systematic Strategies first reported a position in Candel Therapeutics in Q2 2024 and held it in 2 quarters.
  • Cubist Systematic Strategies's Candel Therapeutics position peaked at $162K in Q2 2024.
  • 81 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.